Latest news with #ANIP
Yahoo
30-06-2025
- Business
- Yahoo
The Top 5 Analyst Questions From ANI Pharmaceuticals's Q1 Earnings Call
ANI Pharmaceuticals' first quarter results were marked by substantial top-line growth, but the market responded negatively, with shares falling sharply after the report. Management attributed the quarter's revenue strength to a surge in generics sales, ongoing robust demand for Cortrophin Gel, and increased activity in branded products. CEO Nikhil Lalwani said, 'The first quarter reflected particularly strong performance for our generics business, continued solid demand for Cortrophin Gel, and increased demand for our brands portfolio.' However, margin pressures and near-term challenges in the retina segment weighed on investor sentiment. Is now the time to buy ANIP? Find out in our full research report (it's free). Revenue: $197.1 million vs analyst estimates of $179.6 million (43.4% year-on-year growth, 9.8% beat) Adjusted EPS: $1.70 vs analyst estimates of $1.38 (23% beat) Adjusted EBITDA: $50.75 million vs analyst estimates of $42.4 million (25.7% margin, 19.7% beat) The company lifted its revenue guidance for the full year to $780.5 million at the midpoint from $766 million, a 1.9% increase Management raised its full-year Adjusted EPS guidance to $6.45 at the midpoint, a 2.2% increase EBITDA guidance for the full year is $200 million at the midpoint, above analyst estimates of $195.8 million Operating Margin: 13.3%, down from 14.8% in the same quarter last year Market Capitalization: $1.31 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Gary Nachman (Raymond James) pressed on whether the new pre-filled syringe for Cortrophin Gel could materially expand use and asked about the impact of added sales reps. CEO Nikhil Lalwani said early feedback was positive and that the expanded field force is gaining traction, but no further rep additions are planned for now. Faisal Khurshid (Leerink Partners) sought clarity on commercial access barriers affecting the retina segment, particularly regarding Medicare. Lalwani explained that lack of foundation funding for co-pay support in Q1 reduced access but the company is exploring alternative pathways and expects improvement. Vamil Divan (Guggenheim Securities) asked about the potential impact of upcoming clinical trial results for retina therapies and the significance of Prucalopride exclusivity for generics. Management confirmed that positive trial outcomes could broaden ILUVIEN's use, and that generics revenue will dip post-exclusivity before rebounding. David Amsellem (Piper Sandler) questioned the sustainability of payer dynamics as the Cortrophin category grows and inquired about surprises in the Alimera acquisition. Lalwani asserted that payers value competition in ACTH and expressed confidence in resolving challenges related to the retina portfolio. Ekaterina Knyazkova (J.P. Morgan) probed which indications are driving Cortrophin Gel growth and whether ANI's U.S. manufacturing footprint could be leveraged if tariffs are enacted. Lalwani detailed broad-based growth across specialties and confirmed spare capacity to meet potential tariff-driven demand. In the coming quarters, StockStory analysts will monitor (1) the pace of Cortrophin Gel adoption enabled by the pre-filled syringe and outreach to new prescribers, (2) the recovery in retina segment sales as commercial changes and market access initiatives take effect, and (3) sustained momentum in generics following the expiration of Prucalopride exclusivity. Any developments regarding pharmaceutical tariffs and the ongoing CG Oncology royalty litigation may also influence results. ANI Pharmaceuticals currently trades at $65.50, down from $71.67 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Washington Post
09-05-2025
- Business
- Washington Post
ANI: Q1 Earnings Snapshot
BAUDETTE, Minn. — BAUDETTE, Minn. — ANI Pharmaceuticals Inc. (ANIP) on Friday reported first-quarter earnings of $15.7 million. The Baudette, Minnesota-based company said it had profit of 69 cents per share. Earnings, adjusted for one-time gains and costs, were $1.70 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.37 per share.
Yahoo
15-04-2025
- Business
- Yahoo
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?
Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by 23%. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move. Is there a buying opportunity in ANI Pharmaceuticals, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. We're glad investors have benefited from the price increase, but we don't have much confidence in ANI Pharmaceuticals. Here are three reasons why you should be careful with ANIP and a stock we'd rather own. With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $614.4 million in revenue over the past 12 months, ANI Pharmaceuticals is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. ANI Pharmaceuticals's flat EPS over the last five years was below its 24.4% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded. Growth gives us insight into a company's long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). ANI Pharmaceuticals's five-year average ROIC was negative 6.2%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector. ANI Pharmaceuticals isn't a terrible business, but it doesn't pass our bar. With its shares outperforming the market lately, the stock trades at 13× forward price-to-earnings (or $68.06 per share). Beauty is in the eye of the beholder, but we don't really see a big opportunity at the moment. We're fairly confident there are better stocks to buy right now. We'd recommend looking at one of our top digital advertising picks. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.
Yahoo
08-04-2025
- Business
- Yahoo
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE
Chicago, IL – April 8, 2025 – Stocks in this week's article are ANI Pharmaceuticals, Inc. ANIP, Expand Energy Corporation EXE, Avista Corp AVA and Contango ORE, Inc. CTGO. President Donald Trump's recently imposed tariff has rattled the equity market. The action will weigh on the already slowing domestic economy as the tariff will increase prices of both domestic and imported goods, thereby fueling uncertainty. In this context, creating a curated portfolio of low-beta stocks is a prudent strategy. This provides a safeguard against the uncertain market, equipping investors to navigate volatility with greater resilience and foresight. Hence, stocks like ANI Pharmaceuticals, Inc., Expand Energy Corporation, Avista Corp and Contango ORE, Inc. are worth betting on. Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security's price movement relative to the market. In this article, we are considering the S&P 500 as the market. If a stock has a beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1. For example, if the market offers a return of 20%, a stock with a beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating. Here are four of the eight stocks that qualified for the screening: ANI Pharmaceuticals ANI Pharmaceuticals is a well-established, diversified biopharmaceutical company that is highly committed to offering premium quality medicines that are affordable. Investors applauded ANIP for its recent launch of Nitazoxanide Tablets, 500 mg. ANIP is banking on its Generics business, thanks to the launches of new products. For 2025, the stock has seen upward revisions to earnings estimates over the past 30 days. Expand Energy As a leading producer of natural gas, Expand Energy has been banking on exploding demand for clean energy across the world. EXE is on track to meet its $500 million synergy target this year, thanks to a strong focus on integration and effectively carrying out its plans and strategies. Expand Energy, which is driving to lower its breakeven costs, has witnessed upward earnings estimate revisions for 2025 and 2026 over the past seven days. Avista In the United States, Avista is among the leading utilities responsible for very low carbon emissions. To support its growing and large customer base, AVA has set up a solid capital investment program. From the estimated $525 million capital investment in 2025, AVA is planning to grow its investment to $650 million in 2029, securing a rate base growth of 5% to 6%. Notably, over the past 30 days, the company has witnessed upward earnings estimate revisions for 2025. Contango Contango, a gold explorer, is experiencing an increase in net operating cash flows thanks to the commencement of production at Manh Chox`x`h. The company boasted that through the remaining life of the Manh Choh, it will be able to generate higher cash flows, as roughly 30% of the net gold production from the mine for fiscal years 2025 and 2026 will be linked to spot gold prices. You can get the rest of the stocks on this list by signing up now for your two-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avista Corporation (AVA) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report Contango ORE, Inc. (CTGO) : Free Stock Analysis Report Expand Energy Corporation (EXE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic fibrosis (CF) drug, Kaftrio, to treat all patients aged two years and older who have at least one non-class I mutation in the CFTR gene. This approval was expected as the EMA's Committee for Medicinal Products for Human Use ('CHMP') issued a positive opinion recommending Kaftrio's approval in February for the above indication. With this expanded label, nearly 4,000 more CF patients living in the region are now eligible for treatment with the drug. Kaftrio is already approved for use in CF patients aged two years and older who have at least one F508del mutation in the CFTR gene. The drug is marketed by Vertex for similar indications in the United States under the trade name Trikafta. Year to date, shares of Vertex have gained 18% against the industry's 7% decline. Image Source: Zacks Investment Research Vertex holds a dominant position in the CF market. It was the first company to successfully develop a drug that treats the underlying cause of CF. In addition to Trikafta/Kaftrio, the company markets four other CF medications — the recently approved Alyftrek, Symdeko/Symkevi, Orkambi and Kalydeco. Vertex's CF sales continue to grow, driven by Trikafta/Kaftrio, which added $10.24 billion in product sales in 2024. Sales of the drug were up about 15% year over year, driven by its continued robust performance across all markets. The company aims to have small molecule treatments for most people with CF. In this regard, Vertex is developing an mRNA therapeutic, VX-522, in partnership with Moderna MRNA for approximately 5,000 people with CF who do not make CFTR protein and cannot benefit from its CFTR modulators. A single ascending dose (SAD) portion of a phase I/II clinical study on the Moderna-partnered therapy is complete, while a multiple ascending dose (MAD) portion of the study is ongoing. Data from this Moderna-partnered MAD study is expected in the first half of 2025. Vertex currently carries a Zacks Rank #3 (Hold). Vertex Pharmaceuticals Incorporated price | Vertex Pharmaceuticals Incorporated Quote Some better-ranked stocks from the sector are ANI Pharmaceuticals ANIP and 89bio ETNB. While ANIP sports a Zacks Rank #1 (Strong Buy) at present, ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for ANI Pharmaceuticals' 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period. Year to date, shares of ANIP have risen 21%. ANIP's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%. Estimates for 89bio's loss per share have narrowed from $2.51 to $1.98 for 2025 in the past 60 days. During the same time frame, estimates for 2026 loss per share have improved from $2.94 to $2.15. ETNB's shares have lost 30% year to date. 89bio's earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
